Dry and Wet Age-Related Macular Degeneration | Disease Landscape & Forecast | G7 | 2023
Age-related macular degeneration (AMD) is a degenerative and progressive ocular disease that diminishes central visual acuity as a result of photoreceptor degeneration in the macula. The wet AMD market has long been dominated by three anti-vascular endothelial growth factors (VEGFs) , including Roche / Genentech / Chugai’s off-label compounded Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. We anticipate the newer entrants on the market, Roche / Chugai’s Vabysmo (faricimab) and Regeneron / Bayer’s Eylea HD to continue to experience strong uptake, driven mostly by their advantageous dosing regimen. Competition will increase in the wet AMD market with the launch of emerging therapies including aflibercept biosimilars and Regenxbio / AbbVie’s ABBV-RGX-314, promising lower cost and longer dosing intervals, respectively. By contrast, the management of geographic atrophy (GA) is limited to Apellis’s Syfovre and Astellas’s Izervay, which launched in the United States in 2023. The AMD therapy market in the G7 will grow 6.4% annually and we expect sales to reach over $15.2 billion by 2032.
Questions answered
- How will the wet AMD treatment algorithm change as new products launch?
- To what extent will novel therapies such as Roche’s faricimab capitalize on the need for therapies with longer dosing intervals?
- How will market dynamics be impacted by the launch of biosimilars of Lucentis and Eylea?
- How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
- What will be the impact of Outlook Therapeutics’ Lytenava (ONS-5010) on Avastin if it launches for wet AMD, particularly in the United States?
Content highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 29 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total prevalence of late AMD, by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2032, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase 3 / PR: 6 drugs; Phase 2: 17 drugs; coverage of select Phase 1 products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
